News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
876,820 Results
Type
Article (88339)
Company Profile (734)
Press Release (787715)
Multimedia
Podcasts (225)
Webinars (34)
Section
Business (233409)
Career Advice (4154)
Deals (39941)
Drug Delivery (170)
Drug Development (91520)
Employer Resources (207)
FDA (18460)
Job Trends (17466)
News (398235)
Policy (39976)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
Academia (3039)
Academic (1)
Accelerated approval (48)
Adcomms (35)
Allergies (179)
Alliances (56974)
ALS (217)
Alzheimer's disease (1907)
Antibody-drug conjugate (ADC) (476)
Approvals (18752)
Artificial intelligence (729)
Autoimmune disease (277)
Automation (56)
Bankruptcy (405)
Best Places to Work (12617)
BIOSECURE Act (23)
Biosimilars (235)
Biotechnology (453)
Bladder cancer (188)
Brain cancer (77)
Breast cancer (758)
Cancer (5941)
Cardiovascular disease (502)
Career advice (3586)
Career pathing (48)
CAR-T (347)
CDC (65)
Celiac Disease (3)
Cell therapy (942)
Cervical cancer (47)
Clinical research (78106)
Collaboration (2190)
Company closure (7)
Compensation (1366)
Complete response letters (96)
COVID-19 (3015)
CRISPR (116)
C-suite (1129)
Cystic fibrosis (160)
Data (7737)
Decentralized trials (3)
Denatured (85)
Depression (175)
Dermatology (78)
Diabetes (593)
Diagnostics (7449)
Digital health (55)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (353)
Drug pricing (227)
Drug shortages (35)
Duchenne muscular dystrophy (290)
Earnings (101524)
Editorial (73)
Employer branding (25)
Employer resources (174)
Events (136889)
Executive appointments (1114)
FDA (22178)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (35)
Funding (1779)
Gene editing (252)
Generative AI (69)
Gene therapy (779)
GLP-1 (1183)
Government (5497)
Grass and pollen (7)
Guidances (406)
Healthcare (21028)
HIV (81)
Huntington's disease (61)
IgA nephropathy (97)
Immunology and inflammation (330)
Immuno-oncology (98)
Indications (177)
Infectious disease (3367)
Inflammatory bowel disease (227)
Inflation Reduction Act (17)
Influenza (142)
Intellectual property (292)
Interviews (819)
IPO (17975)
IRA (58)
Job creations (5205)
Job search strategy (2870)
JPM (72)
Kidney cancer (19)
Labor market (109)
Layoffs (667)
Leadership (47)
Legal (10155)
Liver cancer (106)
Longevity (34)
Lung cancer (788)
Lymphoma (431)
Machine learning (61)
Management (66)
Manufacturing (1065)
MASH (196)
Medical device (15138)
Medtech (15237)
Mergers & acquisitions (23159)
Metabolic disorders (1588)
mRNA (238)
Multiple sclerosis (189)
NASH (24)
Neurodegenerative disease (446)
Neuropsychiatric disorders (117)
Neuroscience (3489)
Neurotech (1)
NextGen: Class of 2026 (7692)
Non-profit (5127)
Now hiring (77)
Obesity (761)
Opinion (360)
Ovarian cancer (216)
Pain (259)
Pancreatic cancer (301)
Parkinson's disease (371)
Partnered (37)
Patents (603)
Patient recruitment (672)
Peanut (66)
People (67519)
Pharmaceutical (128)
Pharmacy benefit managers (35)
Phase 1 (24142)
Phase 2 (33940)
Phase 3 (25521)
Pipeline (8108)
Policy (371)
Postmarket research (3556)
Preclinical (10868)
Press Release (72)
Prostate cancer (300)
Psychedelics (64)
Radiopharmaceuticals (343)
Rare diseases (1142)
Real estate (7451)
Recruiting (81)
Regulatory (29869)
Reports (76)
Research institute (2751)
Resumes & cover letters (653)
Rett syndrome (37)
RNA editing (26)
RSV (91)
Schizophrenia (188)
Series A (306)
Series B (220)
Service/supplier (27)
Sickle cell disease (119)
Special edition (30)
Spinal muscular atrophy (186)
Sponsored (54)
Startups (4359)
State (2)
Stomach cancer (19)
Supply chain (132)
Tariffs (98)
The Weekly (137)
Vaccines (1231)
Venture capital (118)
Weight loss (513)
Women's health (125)
Worklife (24)
Date
Today (198)
Last 7 days (813)
Last 30 days (2988)
Last 365 days (31894)
2026 (11150)
2025 (31826)
2024 (37543)
2023 (42564)
2022 (53928)
2021 (58721)
2020 (57664)
2019 (51336)
2018 (39119)
2017 (37189)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1293)
Alabama (100)
Alaska (7)
Arizona (376)
Arkansas (16)
Asia (51969)
Australia (9142)
California (13233)
Canada (3733)
China (1396)
Colorado (567)
Connecticut (572)
Delaware (399)
Europe (119559)
Florida (1967)
Georgia (424)
Hawaii (4)
Idaho (69)
Illinois (1101)
India (95)
Indiana (603)
Iowa (25)
Japan (528)
Kansas (138)
Kentucky (54)
Louisiana (44)
Maine (80)
Maryland (1621)
Massachusetts (9614)
Michigan (371)
Minnesota (728)
Mississippi (7)
Missouri (147)
Montana (36)
Nebraska (30)
Nevada (143)
New Hampshire (88)
New Jersey (3509)
New Mexico (32)
New York (3488)
North Carolina (1791)
North Dakota (10)
Northern California (6535)
Ohio (390)
Oklahoma (26)
Oregon (53)
Pennsylvania (2636)
Puerto Rico (29)
Rhode Island (52)
South America (1667)
South Carolina (85)
South Dakota (2)
Southern California (5161)
Tennessee (209)
Texas (2107)
United States (47197)
Utah (394)
Vermont (1)
Virginia (325)
Washington D.C. (85)
Washington State (1088)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
876,820 Results for "mustang bio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Climb Bio, Inc. Announces $110.0 Million Private Placement
April 28, 2026
·
6 min read
Press Releases
/U P D A T E -- Nuvation Bio Inc./
April 22, 2026
·
14 min read
Press Releases
Takara Bio USA, Inc. Validates New Class of Spatial Technology with Benchmark Study for Cancer Research
April 20, 2026
·
3 min read
Press Releases
INmune Bio Inc. Announces 2025 Results and Provides Business Update
March 30, 2026
·
15 min read
Press Releases
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
April 30, 2026
·
3 min read
Business
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
March 11, 2024
·
15 min read
Press Releases
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and Single-Cell Technologies
April 17, 2026
·
5 min read
Deals
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,130,000 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.41 per share.
June 20, 2024
·
7 min read
Press Releases
Mustang Bio Announces Closing of $8 Million Public Offering
February 11, 2025
·
5 min read
Genetown
Mustang Bio Announces Pricing of $4 Million Public Offering
Mustang Bio, Inc. announced the pricing of a public offering of an aggregate of 16,877,638 shares of its common stock, Series A-1 warrants to purchase up to 16,877,638 shares of common stock, Series A-2 warrants to purchase up to 16,877,638 shares of common stock and Series A-3 warrants to purchase up to 16,877,638 shares of common stock, at a combined public offering price of $0.237 per share and accompanying warrants.
April 29, 2024
·
6 min read
1 of 87,682
Next
